Details:

Personal Author:
Bennett, Nancy M.; Whitney, Cynthia G.; Moore, Matt; Pilishvili, Tamara; Dooling, Kathleen L.;
Bennett, Nancy M.; Whitney, Cynthia G.; Moore, Matt; Pilishvili, Tamara; Dooling, Kathleen L.; Less -
Corporate Authors:
National Center for Immunization and Respiratory Diseases (U.S.); United States. Advisory Committee on Immunization Practices. Pneumococcal Work Group;
National Center for Immunization and Respiratory Diseases (U.S.); United States. Advisory Committee on Immunization Practices. Pneumococcal Work Group; Less -
Description:
MMWR. Morbidity and mortality weekly report 2012 Oct 12;61(40):816-9. Reported by: Nancy M. Bennett, MD, Advisory Committee on Immunization Practices Pneumococcal Work Group. Cynthia G. Whitney, MD, Matt Moore, MD, Tamara Pilishvili, MPH, Respiratory Diseases Br, Div of Bacterial Diseases, National Center for Immunization and Respiratory Diseases; Kathleen L. Dooling, MD, EIS Officer, CDC. On June 20, 2012, the Advisory Committee on Immunization Practices (ACIP) recommended routine use of 13-valent pneumococcal conjugate vaccine (PCV13; Prevnar 13, Wyeth Pharmaceuticals, Inc., a subsidiary of Pfizer, Inc.) for adults aged ≥19 years with immunocompromising conditions, functional or anatomic asplenia, cerebrospinal fluid (CSF) leaks, or cochlear implants. PCV13 should be administered to eligible adults in addition to the 23-valent pneumococcal polysaccharide vaccine (PPSV23; Pneumovax 23, Merck & Co. Inc.), the vaccine currently recommended for these groups of adults. The evidence for the benefits and risk of PCV13 vaccination of adults with immunocompromising conditions was evaluated using the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) framework and designated as a Category A recommendation. This report outlines the new ACIP recommendations for PCV13 use; explains the recommendations for the use of PCV13 and PPSV23 among adults with immunocompromising conditions, functional or anatomic asplenia, CSF leaks, or cochlear implants; and summarizes the evidence considered by ACIP to make its recommendations. Recommendations for routine use of vaccines in children and adolescents are developed by the Advisory Committee on Immunization Practices (ACIP). ACIP is chartered as a federal advisory committee to provide expert external advice and guidance to the Director of CDC on use of vaccines in the civilian population of the United States. Recommendations are harmonized to the greatest extent possible with recommendations made by the American Academy of Pediatrics (AAP), the American Academy of Family Physicians (AAFP), and the American College of Obstetrics and Gynecology (ACOG). Recommendations for routine use of vaccines in adults are harmonized with recommendations of AAFP, ACOG, and the American College of Physicians. ACIP recommendations adopted by the Director of CDC become recommendations of the agency on the date published in MMWR.
Subject:
[+]
Adult
Advisory Committees
Aged
Cerebrospinal Fluid Rhinorrhea
Cochlear Implants
Cost-Benefit Analysis
Humans
Immunization Schedule
Immunocompromised Host
Middle Aged
Pneumococcal Infections/prevention & Control
Pneumococcal Vaccines/administration & Dosage
Pneumococcal Vaccines/economics
Pneumococcal Vaccines/immunology
Practice Guidelines As Topic
Randomized Controlled Trials As Topic
Spleen/abnormalities
Splenectomy
Streptococcus Pneumoniae
Young Adult

Document Type:
Journal Article;
Genre:
Practice Guideline;
Place as Subject:
United States;
Collection(s):
Guidelines and Recommendations
Advisory Committee on Immunization Practices (ACIP)
Main Document Checksum:
[+]
urn:sha256:a3b914abce40212b202b4ef5687fc65c5c3a2ff626e5d13a5ea47fe6599121bb
File Type:

Supporting Files

• No Additional Files

More +